Literature DB >> 29858613

The synthetic cannabinoid 5F-AMB changes the balance between excitation and inhibition of layer V pyramidal neurons in the mouse medial prefrontal cortex.

Masaki Domoto1, Hitoki Sasase1, Shintaro Wada1, Shiho Ito1, Satoshi Deyama1, Eiichi Hinoi1, Shuji Kaneko2, Katsuyuki Kaneda3.   

Abstract

RATIONALE: 5F-AMB is one of the synthetic cannabinoids (SCs) designed to potentiate the ability to activate cannabinoid 1 (CB1) receptors and is abused worldwide. Although inhalation of 5F-AMB elicits serious adverse effects including impaired memory and consciousness, it is not known whether and how 5F-AMB affects the activity of pyramidal neurons in the medial prefrontal cortex (mPFC), a brain region associated with higher functions such as memory and cognition.
OBJECTIVES: In the present study, we examined the effects of 5F-AMB on mPFC layer V (L5) pyramidal neurons using in vitro whole-cell patch-clamp recordings.
RESULTS: Bath application of 5F-AMB attenuated the frequency but not the amplitude of spontaneous excitatory and inhibitory postsynaptic currents (sEPSCs and sIPSCs). The attenuating effects of 5F-AMB were abolished by the CB1 receptor antagonist AM251. 5F-AMB also attenuated the frequency of miniature EPSCs and IPSCs recorded in the presence of tetrodotoxin. Moreover, the extent of attenuating effects of 5F-AMB on stimulus-evoked EPSCs was significantly larger than that on evoked IPSCs.
CONCLUSIONS: These findings suggest that 5F-AMB attenuates both excitatory and inhibitory transmission in mPFC L5 pyramidal neurons via the activation of CB1 receptors located in presynaptic terminals. Further, the net impact of 5F-AMB on L5 pyramidal neurons is inhibition due to the change in balance between excitation and inhibition. This inhibitory effect might at least partly contribute to the expression of the adverse effects induced by 5F-AMB inhalation.

Entities:  

Keywords:  5F-AMB; CB1 receptor; Designer drug; Layer V pyramidal neurons; Medial prefrontal cortex; Synthetic cannabinoids

Mesh:

Substances:

Year:  2018        PMID: 29858613     DOI: 10.1007/s00213-018-4933-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  Dysfunctional prefrontal cortical network activity and interactions following cannabinoid receptor activation.

Authors:  Michal T Kucewicz; Mark D Tricklebank; Rafal Bogacz; Matthew W Jones
Journal:  J Neurosci       Date:  2011-10-26       Impact factor: 6.167

Review 2.  Endocannabinoid-mediated control of synaptic transmission.

Authors:  Masanobu Kano; Takako Ohno-Shosaku; Yuki Hashimotodani; Motokazu Uchigashima; Masahiko Watanabe
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

3.  Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons.

Authors:  N Auclair; S Otani; P Soubrie; F Crepel
Journal:  J Neurophysiol       Date:  2000-06       Impact factor: 2.714

Review 4.  The role of medial prefrontal cortex in memory and decision making.

Authors:  David R Euston; Aaron J Gruber; Bruce L McNaughton
Journal:  Neuron       Date:  2012-12-20       Impact factor: 17.173

Review 5.  Role of endogenous cannabinoids in synaptic signaling.

Authors:  Tamas F Freund; Istvan Katona; Daniele Piomelli
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

6.  Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons.

Authors:  Juan Guo; Stephen R Ikeda
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

7.  Activation of type-1 cannabinoid receptor shifts the balance between excitation and inhibition towards excitation in layer II/III pyramidal neurons of the rat prelimbic cortex.

Authors:  Femke S den Boon; Taco R Werkman; Qiluan Schaafsma-Zhao; Kas Houthuijs; Tania Vitalis; Chris G Kruse; Wytse J Wadman; Pascal Chameau
Journal:  Pflugers Arch       Date:  2014-08-02       Impact factor: 3.657

8.  Motivation and cognitive control in the human prefrontal cortex.

Authors:  Frédérique Kouneiher; Sylvain Charron; Etienne Koechlin
Journal:  Nat Neurosci       Date:  2009-06-07       Impact factor: 24.884

Review 9.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

Review 10.  Emerging drugs of abuse: current perspectives on synthetic cannabinoids.

Authors:  Danièle Debruyne; Reynald Le Boisselier
Journal:  Subst Abuse Rehabil       Date:  2015-10-20
View more
  3 in total

Review 1.  How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.

Authors:  Raquel Santos-Toscano; Amira Guirguis; Colin Davidson
Journal:  Br J Clin Pharmacol       Date:  2020-02-23       Impact factor: 4.335

2.  Selective inhibition of monoacylglycerol lipase is associated with passive coping behavior and attenuation of stress-induced dopamine release in the medial prefrontal cortex.

Authors:  Francisco Javier Pavón; Ilham Y Polis; David G Stouffer; Benjamin F Cravatt; Marisa Roberto; Rémi Martin-Fardon; Fernando Rodríguez de Fonseca; Loren H Parsons; Antonia Serrano
Journal:  Neurobiol Stress       Date:  2021-01-09

Review 3.  Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications.

Authors:  Arianna Giorgetti; Jennifer P Pascali; Paolo Fais; Guido Pelletti; Andrea Gabbin; Giorgia Franchetti; Giovanni Cecchetto; Guido Viel
Journal:  Life (Basel)       Date:  2021-05-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.